Tech Company Financing Transactions
Apitope Funding Round
Apitope, operating out of Chepstow, raised $13.5 million from Wales Life Sciences Fund and private investors.
Transaction Overview
Company Name
Announced On
9/30/2015
Transaction Type
Venture Equity
Amount
$13,500,000
Round
Series B
Investors
Wales Life Sciences Fund (Lead Investor) (Brenig Preest)
Proceeds Purpose
The funds will enable Apitope to progress the clinical development of its innovative pipeline which includes therapies for Factor VIII intolerance in Haemophilia A patients and Graves' disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Riverside Ct. Beaufort Park
Chepstow, NP16 5UH
UK
Chepstow, NP16 5UH
UK
Phone
Undisclosed
Website
Email Address
Overview
Apitope is a privately owned European biotech company developing antigen specific therapeutic peptides for the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves' disease, Uveitis, and others.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hayley French
Chief Medical Officer
Christina Carnegie
Chief Scientific Officer
David Wraith
VP - Human Resources
Luc Lammens
VP - R & D
Liselotte Jansson
Browse more venture capital transactions:
Prev: 9/30/2015: Narvii venture capital transaction
Next: 9/30/2015: Pingplot venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs